Duchenne Muscular Dystrophy Market Projected to Grow 11% Annually by 2036

The market for Duchenne Muscular Dystrophy (DMD) is experiencing significant growth, projected to expand at an 11% compound annual growth rate (CAGR) through 2036. This expansion is primarily fueled by advancements in gene therapies and disease-modifying treatments, coupled with increased genetic screening and earlier diagnosis.

According to a report by market research firm DelveInsight, the DMD market was valued at approximately USD 4 billion in 2025. The seven major markets (United States, EU4, UK, and Japan) accounted for an estimated 32,000 prevalent cases of DMD in 2025, with the United States representing the largest share at around 17,500 cases.

The current treatment landscape includes corticosteroids like prednisone and deflazacort, alongside mutation-specific exon-skipping therapies. The development and adoption of new therapies such as ELEVIDYS, VYONDYS 53, VILTEPSO, and EXONDYS 51 are expected to further stimulate market growth. VILTEPSO was the highest revenue-generating DMD therapy in 2025, accounting for approximately USD 560 million.

The report highlights several key factors driving market expansion. These include advanced gene and exon-skipping therapies aimed at addressing the underlying genetic defect, and a robust pipeline of drug candidates in clinical development. Regulatory support for rare diseases and increasing healthcare investment are also contributing to the development and accessibility of new treatments.

Leading companies in DMD therapy development include Sarepta Therapeutics, PTC Therapeutics, and Nippon Shinyaku. Ongoing research continues to support the development of promising new treatments like Pizuglanstat and RGX-202. Growing awareness and improved diagnostic methods are facilitating earlier patient identification and intervention.